Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2020-03-25 Regulatory Filings
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Pause in trading 1 page 110.2KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It is a brief regulatory announcement without financial data, report content, or detailed analysis. It does not fit into categories like financial reports, management information, or capital updates. It is best classified as a Regulatory Filing (RNS) as a general regulatory announcement.
2020-03-25 English
Trading Halt 2 pages 284.3KB
Regulatory Filings Classification · 100% confidence The document is a market announcement regarding a trading halt requested by Lifespot Health Ltd. It is a short notice informing the market about the halt of trading pending an upcoming announcement. There is no financial data, report content, or detailed analysis present. The document is clearly an announcement related to trading status rather than a financial report or detailed filing. According to the classification rules, such announcements fall under Regulatory Filings (RNS) as a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-03-25 English
BodyTel Platform to be Extended to Fever Tracking 2 pages 195.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Lifespot Health Limited dated 25th March 2020. It discusses the extension of the BodyTel platform to include Bluetooth-enabled thermometers for fever tracking, particularly in response to the COVID-19 pandemic. The content focuses on product development, market needs, and ongoing negotiations for distribution. There are no financial statements, regulatory certifications, voting results, or management changes mentioned. The document is an announcement of a product and business update rather than a financial report or regulatory filing. It is approximately 4805 characters, which is relatively short and consistent with an announcement rather than a detailed report. Therefore, the most appropriate classification is a Regulatory Filing (RNS) as a general announcement that does not fit into more specific categories like financial reports, management changes, or capital updates.
2020-03-24 English
Section 708A Notice 1 page 153.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement regarding the issue of ordinary shares by Lifespot Health Limited. It references Section 708A of the Corporations Act 2001, which relates to exemptions for the sale of securities issued without disclosure. The document provides formal notification of the share issue and compliance with relevant legal provisions. It does not contain financial statements, management discussion, or detailed financial data. The document length is short (1334 characters) and serves as a regulatory announcement about a capital transaction. Therefore, it fits best under Capital/Financing Update (CAP).
2020-03-01 English
Preliminary Final Report 9 pages 261.0KB
Annual Report Classification · 95% confidence The document is titled 'Lifespot Health Ltd Appendix 4E Preliminary final report' and covers the financial year ended 31 December 2019. It includes detailed financial statements such as the statement of profit or loss, statement of financial position, statement of changes in equity, statement of cash flows, and notes to the financial statements. The document contains comprehensive financial data and analysis for the full fiscal year, including revenues, losses, assets, liabilities, equity, and detailed notes. The presence of a preliminary final report and detailed financial statements for the full year indicates this is an annual report type document. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are annual reports but preliminary in nature. Given the detailed financial data and the full year coverage, this document fits the definition of an Annual Report (10-K equivalent). It is not a short announcement or a certification, but a full financial report with substantive data and analysis. FY 2019
2020-02-27 English
2019 Preliminary Results 3 pages 170.5KB
Annual Report Classification · 95% confidence The document is titled '2019 Preliminary Results' and provides a summary of the company's financial performance for the full fiscal year 2019, including sales figures, comprehensive loss, and business developments. It discusses operational highlights, product developments, and future outlook. The document contains substantive financial data and analysis for the full year 2019, indicating it is a full annual financial report rather than a brief earnings release or announcement. The length of the document (5801 characters) and the detailed financial and operational information support classification as an Annual Report (10-K equivalent). There is no indication that this is merely an announcement of a report or a certification letter, so it is not RPA or RNS. Therefore, the appropriate classification is Annual Report (10-K). FY 2019
2020-02-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.